NWI Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

NWI Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25,000	Closed	-$1.09M	–	57
2023 Q3	$1.09M	Hold	25,000	–	–	0.05%	41
2023 Q2	$903K	Hold	25,000	–	–	0.16%	41
2023 Q1	$930K	Hold	25,000	–	–	0.1%	45
2022 Q4	$1.13M	Hold	25,000	–	–	0.25%	38
2022 Q3	$1.75M	Hold	25,000	–	–	0.31%	39
2022 Q2	$1.68M	Hold	25,000	–	–	0.1%	48
2022 Q1	$2.06M	Hold	25,000	–	–	0.24%	37
2021 Q4	$3.67M	Hold	25,000	–	–	0.24%	40
2021 Q3	$4.42M	Buy	+25,000	New	+$4.02M	0.27%	39

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

NWI Management's MRTX Position: Q4 2023 in Review

NWI Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 25,000 shares — an estimated $1.09M sold.

NWI Management first reported a position in MRTX in Q3 2021 and held it in 9 quarters. The position peaked at $4.42M in Q3 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

NWI Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
NWI Management sold 25,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $1.09M.
NWI Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2021 and held it in 9 quarters.
NWI Management's Mirati Therapeutics, Inc. Common Stock position peaked at $4.42M in Q3 2021.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on NWI Management's 13F filing for Q4 2023, filed 15 Feb 2024.